Renaissance Capital logo

Forte Biosciences (Tocagen) Priced, Nasdaq: FBRX

Developing a combination gene therapy treatment for brain cancer.

Industry: Health Care

First Day Return: +24.5%

Industry: Health Care

We are a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly-applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Our cancer-selective gene therapy platform is built on retroviral replicating vectors, or RRVs, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Our gene therapy approach is designed to fight cancer through immunotherapeutic mechanisms of action without the autoimmune toxicities commonly experienced with other immunotherapies. Our founding vision is "No One Should Die Of Cancer" because we believe the immune system can be safely activated to fight the patient’s cancer.
more less
IPO Data
IPO File Date 03/09/2017
Offer Price $10.00
Price Range $10.00 - $12.00
Offer Shares (mm) 8.5
Deal Size ($mm) $85
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 04/12/2017
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $85
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters San Diego, CA, United States
Founded 2007
Employees at IPO 61
Website www.tocagen.com

Forte Biosciences (Tocagen) (FBRX) Performance